Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983528 · ClinicalTrials.gov registry record · Phase 1
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00983528 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 6 participants.
The verdict
NCT00983528, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Clofarabine is approved by the FDA for the treatment of pediatric patients (1 to 21 years of age) with relapsed or refractory ALL. Alemtuzumab is approved by the FDA for treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients over the age of 18. These drugs have been used to treat patients with leukemia in other research studies like this one. Both drugs have individually been administered to adult patients with ALL with acceptable toxicity profiles. This study will evaluate the combination of clofarabine and alemtuzumab when administered to adult patients with relapsed or refractory ALL. Primary objectives of the study is to determine the maximum tolerated dose of clofarabine when administered with alemtuzumab, evaluate the safety of the combination, and assess for activity of the combination by evaluating response rate, effect on ALL progenitor cell population, and patients who are able to bridge to transplant.
Interventions
- DRUG Clofarabine
- BIOLOGICAL Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983528
The ClinicalTrials.gov registry entry for NCT00983528 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clofarabine is the first listed.
NCT00983528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983528 about?
NCT00983528 is a clinical study titled "Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia". Clofarabine is approved by the FDA for the treatment of pediatric patients (1 to 21 years of age) with relapsed or refractory ALL. Alemtuzumab is approved by the FDA for treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients over the age of 18. These drugs have been used to treat patie...
What is the current status of trial NCT00983528?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-09. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00983528?
The interventions under investigation include: Clofarabine (DRUG), Alemtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00983528?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.